You are here: Home » PTI Stories » National » News
Business Standard

Lupin launches generic prostatic hyperplasia treatment drug in US

Press Trust of India  |  New Delhi 

Drug firm Tuesday said it has launched generic capsules, used for of benign enlargement of the gland, in the US market.

The company has launched its capsules in the strengths of 4 mg and 8 mg after receiving an approval from the Food and Drug Administration (USFDA) earlier, the company said in a statement.

The company's product is generic equivalent of Allergan's Rapaflo capsules, it added.

As per IQVIA MAT September 2018 data, Rapaflo had annual sales of USD 198.5 million in the US, said.

The capsules are indicated for the of (BPH), it added.

Shares of today closed at Rs 888.05 per scrip on BSE, down 1.14 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, December 04 2018. 17:15 IST